Men With Advanced Prostate Cancer, Be Informed About Your Genetics!

Video
Conference|ASCO Annual Meeting: Genitourinary

In this video, Dr. Heather Cheng briefly outlines the GENTleMEN study on the impact of genetic testing for men with advanced prostate cancer. 

In this video, Dr. Heather Cheng briefly outlines the GENTleMEN study of the impact of genetic testing for men with advanced prostate cancer.

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content
Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups

Kristi Rosa
July 10th 2025
Article

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups

Kristi Rosa
July 9th 2025
Article

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.